Tuesday, November 12, 2013

2013 National Brain Tumor Society Summit Presentations

I didn’t attend this summit, but wish I did. 

To make up for it, I watched the keynote address from Dr. Webster Cavenee, “…a world renowned researcher and long standing, trusted advisor, from Ludwig Institute for Cancer Research and the University of California San Diego.” According to the NBTS website he delivered  “…a keynote presentation describing our most innovative strategic research initiative to date, our Defeat GBM Research Collaborative, and the potential for a future global model of integrated brain cancer research.”

His presentation is informative, straight-forward and pretty blunt about the complexity and difficulty of the task at hand. Here’s a link: http://www.braintumor.org/about-us/nbts-summit/

On the same web page is a link to the presentation by Michael Nathanson, Chairman of the NBTS Board of Directors, about work being done by the National Brain Tumor Society,  in which he discussed:

“Our Clinical Trial Endpoints Initiative – a program with the support of the U.S. Food and Drug Administration (FDA) aimed at increasing the volume and speed of approvals for new treatment;

Advancing Research to Therapies (ART) for Brain Tumors – a new program aiming to translate laboratory science into commercialized treatments by bringing together researchers, biotech and pharma executives, investors, and patients;

Advocating for Oral Chemotherapy Parity legislation protecting patients from paying out-of-pocket for life-saving treatments just because they are prescribed in pill form; and much more.”

Lastly, the site also provides a link to Summit’s “The State of Research Breakfast” presentation in which experts in the field and National Brain Tumor Society leadership briefed the audience on the “current state of pediatric brain tumor research and the future of our work.”

No comments: